Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

Michael Benatar; Donald B. Sanders; Gil I. Wolfe; Michael P. McDermott; Rabi Tawil

doi:10.1111/j.1749-6632.2012.06780.x

Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

Michael Benatar, Donald B. Sanders, Gil I. Wolfe, Michael P. McDermott, Rabi Tawil

Neurology

Research output: Contribution to journal › Article

22 Scopus citations

Abstract

Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

Original language	English (US)
Pages (from-to)	17-22
Number of pages	6
Journal	Annals of the New York Academy of Sciences
Volume	1275
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.2012.06780.x
State	Published - Dec 2012

Fingerprint

Keywords

Clinical trial
Evidence-based medicine
Ocular myasthenia
Steroids

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
History and Philosophy of Science

Cite this

Benatar, M., Sanders, D. B., Wolfe, G. I., McDermott, M. P., & Tawil, R. (2012). Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. Annals of the New York Academy of Sciences, 1275(1), 17-22. https://doi.org/10.1111/j.1749-6632.2012.06780.x

@article{f4e869d3aacd41dbb2b9a520af5b5db6,

title = "Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial",

abstract = "Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.",

keywords = "Clinical trial, Evidence-based medicine, Ocular myasthenia, Steroids",

author = "Michael Benatar and Sanders, {Donald B.} and Wolfe, {Gil I.} and McDermott, {Michael P.} and Rabi Tawil",

year = "2012",

month = dec

doi = "10.1111/j.1749-6632.2012.06780.x",

language = "English (US)",

volume = "1275",

pages = "17--22",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

AU - Benatar, Michael

AU - Sanders, Donald B.

AU - Wolfe, Gil I.

AU - McDermott, Michael P.

AU - Tawil, Rabi

PY - 2012/12

Y1 - 2012/12

N2 - Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

AB - Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

KW - Clinical trial

KW - Evidence-based medicine

KW - Ocular myasthenia

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84871591629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871591629&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2012.06780.x

DO - 10.1111/j.1749-6632.2012.06780.x

M3 - Article

C2 - 23278573

AN - SCOPUS:84871591629

VL - 1275

SP - 17

EP - 22

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -

Access to Document

10.1111/j.1749-6632.2012.06780.x